4512.T
Wakamoto Pharmaceutical Co.,Ltd. [4512.T] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
4512.T Stock Summary
Top 10 Correlated ETFs
4512.T
Top 10 Correlated Stocks
4512.T
In the News
4512.T Financial details
Company Rating
Buy
Market Cap
8.05B
Income
-177.67M
Revenue
7.98B
Book val./share
337.15
Cash/share
102.59
Dividend
3
Dividend %
1.38%
Employees
403
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
-119.57
Forward P/E
-
PEG
6.85
P/S
0.91
P/B
0.63
P/C
2.27
P/FCF
-
Quick Ratio
3.2
Current Ratio
4.4
Debt / Equity
0.01
LT Debt / Equity
-
-
-
EPS (TTM)
-5.12
EPS next Y
-
EPS next Q
-
EPS this Y
-42.07%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
-4.22%
Revenue Q/Q
11.94%
EPS Q/Q
-105.36%
-
-
-
-
SMA20
8.41%
SMA50
10.48%
SMA100
16%
Inst Own
-
Inst Trans
-
ROA
-
ROE
-1%
ROC
-0.01%
Gross Margin
46%
Oper. Margin
-1%
Profit Margin
-1%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
189.0-261.0
52W High
-10.73%
52W Low
+23.28%
RSI
56
Rel Volume
0.95
Avg Volume
156.63K
Volume
149.1K
Perf Week
0.43%
Perf Month
16.5%
Perf Quarter
10.95%
Perf Half Y
9.91%
-
-
-
-
Beta
0.541
-
-
Volatility
2.76%, 9.75%
Prev Close
1.75%
Price
233
Change
1.75%
4512.T Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-03-31
| Metric | History | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 309.5 | 314.57 | 256.28 | 241.54 | 249.53 | |
| Net income per share | -5.22 | -47.73 | -17.34 | 6.87 | 3.98 | |
| Operating cash flow per share | -3.3 | -4.47 | 4.71 | 9.77 | 18.21 | |
| Free cash flow per share | -20.48 | -10.44 | -9.19 | -0.83 | 12.12 | |
| Cash per share | 91.96 | 83.09 | 81.94 | 93.12 | 111.77 | |
| Book value per share | 396.48 | 344.23 | 328.05 | 330.79 | 343.06 | |
| Tangible book value per share | 382.88 | 330.25 | 322.25 | 325.14 | 337.24 | |
| Share holders equity per share | 396.48 | 344.23 | 328.05 | 330.79 | 343.06 | |
| Interest debt per share | 5.47 | 4.79 | 4.95 | 3.74 | 3.99 | |
| Market cap | 9.82B | 7.98B | 14.85B | 10.03B | 8.57B | |
| Enterprise value | 6.75B | 5.26B | 12.18B | 6.93B | 4.83B | |
| P/E ratio | -54.18 | -4.82 | -24.68 | 42.05 | 62.01 | |
| Price to sales ratio | 0.91 | 0.73 | 1.67 | 1.2 | 0.99 | |
| POCF ratio | -85.79 | -51.48 | 90.89 | 29.57 | 13.57 | |
| PFCF ratio | -13.82 | -22.03 | -46.59 | -346.27 | 20.37 | |
| P/B Ratio | 0.71 | 0.67 | 1.3 | 0.87 | 0.72 | |
| PTB ratio | 0.71 | 0.67 | 1.3 | 0.87 | 0.72 | |
| EV to sales | 0.63 | 0.48 | 1.37 | 0.83 | 0.56 | |
| Enterprise value over EBITDA | 63.97 | -12.01 | -101.45 | 12.64 | 7.44 | |
| EV to operating cash flow | -58.94 | -33.95 | 74.54 | 20.42 | 7.65 | |
| EV to free cash flow | -9.49 | -14.53 | -38.21 | -239.15 | 11.48 | |
| Earnings yield | -0.02 | -0.21 | -0.04 | 0.02 | 0.02 | |
| Free cash flow yield | -0.07 | -0.05 | -0.02 | 0 | 0.05 | |
| Debt to equity | 0.01 | 0.01 | 0.02 | 0.01 | 0.01 | |
| Debt to assets | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Net debt to EBITDA | -29.14 | 6.2 | 22.26 | -5.66 | -5.76 | |
| Current ratio | 3.55 | 3.55 | 4.46 | 4.29 | 4.18 | |
| Interest coverage | -234.28 | -1.49K | -1.33K | -23.28 | 244.75 | |
| Income quality | 0.5 | 0.17 | -0.23 | 1.19 | 2.99 | |
| Dividend Yield | 0.01 | 0 | 0 | 0 | 0 | |
| Payout ratio | -0.57 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0.15 | 0.16 | 0.07 | 0.07 | 0.07 | |
| Intangibles to total assets | 0.03 | 0.03 | 0.01 | 0.01 | 0.01 | |
| Capex to operating cash flow | 5.21 | 1.34 | -2.95 | -1.09 | -0.33 | |
| Capex to revenue | -0.06 | -0.02 | -0.05 | -0.04 | -0.02 | |
| Capex to depreciation | -1.27 | -0.45 | -1 | -0.78 | -0.47 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 215.85 | 608 | 357.77 | 226.17 | 175.35 | |
| ROIC | -0.02 | -0.15 | -0.06 | 0 | 0.01 | |
| Return on tangible assets | -0.01 | -0.11 | -0.04 | 0.02 | 0.01 | |
| Graham Net | 93.41 | 72.71 | 79.16 | 88.87 | 102.37 | |
| Working capital | 6.92B | 6.21B | 5.93B | 6.6B | 7.11B | |
| Tangible asset value | 13.29B | 11.46B | 11.18B | 11.28B | 11.7B | |
| Net current asset value | 5.62B | 4.61B | 4.45B | 5.14B | 5.55B | |
| Invested capital | 0.01 | 0.01 | 0.02 | 0.01 | 0.01 | |
| Average receivables | 3.82B | 3.51B | 3.04B | 2.87B | 3.13B | |
| Average payables | 1.24B | 1.38B | 1.12B | 968.95M | 1.08B | |
| Average inventory | 2.29B | 2.47B | 2.21B | 2.1B | 2.1B | |
| Days sales outstanding | 127.59 | 108.96 | 115.51 | 127.69 | 140.6 | |
| Days payables outstanding | 106.49 | 108.77 | 68.69 | 100.47 | 83.51 | |
| Days of inventory on hand | 195.32 | 190.37 | 162.23 | 204.01 | 156.58 | |
| Receivables turnover | 2.86 | 3.35 | 3.16 | 2.86 | 2.6 | |
| Payables turnover | 3.43 | 3.36 | 5.31 | 3.63 | 4.37 | |
| Inventory turnover | 1.87 | 1.92 | 2.25 | 1.79 | 2.33 | |
| ROE | -0.01 | -0.14 | -0.05 | 0.02 | 0.01 | |
| Capex per share | -17.18 | -5.97 | -13.9 | -10.61 | -6.08 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q3
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 64.78 | 68.93 | 53.6 | 50.65 | 56.7 | |
| Net income per share | 3.8 | 0.8 | 2.9 | -9.32 | 0.5 | |
| Operating cash flow per share | 6.39 | 6.17 | 5.75 | 5.74 | 5.99 | |
| Free cash flow per share | 6.39 | 6.17 | 5.75 | 5.74 | 5.99 | |
| Cash per share | 106.01 | 111.77 | 120.57 | 114.15 | 102.59 | |
| Book value per share | 339.06 | 343.06 | 345.84 | 346.68 | 337.15 | |
| Tangible book value per share | 334.4 | 337.24 | 339.93 | 339.97 | 327.78 | |
| Share holders equity per share | 339.06 | 343.06 | 345.84 | 346.68 | 337.15 | |
| Interest debt per share | 2.88 | 3.98 | 2.89 | 2.88 | 2.89 | |
| Market cap | 7.7B | 8.57B | 7.91B | 7.74B | 7.39B | |
| Enterprise value | 4.13B | 4.83B | 3.83B | 3.88B | 3.93B | |
| P/E ratio | 14.6 | 77.01 | 19.63 | -5.98 | 107.05 | |
| Price to sales ratio | 3.43 | 3.58 | 4.25 | 4.4 | 3.76 | |
| POCF ratio | 34.77 | 40.05 | 39.67 | 38.83 | 35.59 | |
| PFCF ratio | 34.77 | 40.05 | 39.67 | 38.83 | 35.59 | |
| P/B Ratio | 0.65 | 0.72 | 0.66 | 0.64 | 0.63 | |
| PTB ratio | 0.65 | 0.72 | 0.66 | 0.64 | 0.63 | |
| EV to sales | 1.84 | 2.02 | 2.06 | 2.21 | 2 | |
| Enterprise value over EBITDA | 26.67 | 42.45 | -134.8 | -14.23 | 22.79 | |
| EV to operating cash flow | 18.62 | 22.57 | 19.19 | 19.46 | 18.93 | |
| EV to free cash flow | 18.62 | 22.57 | 19.19 | 19.46 | 18.93 | |
| Earnings yield | 0.02 | 0 | 0.01 | -0.04 | 0 | |
| Free cash flow yield | 0.03 | 0.02 | 0.03 | 0.03 | 0.03 | |
| Debt to equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Debt to assets | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Net debt to EBITDA | -23.13 | -32.88 | 143.82 | 14.17 | -20.06 | |
| Current ratio | 4.76 | 4.18 | 4.89 | 4.4 | 4.52 | |
| Interest coverage | 1.24K | 569.21 | -407.71 | -2.79K | 476.78 | |
| Income quality | 1.68 | 7.69 | 1.98 | -0.62 | 12.03 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0.06 | 0.06 | 0.07 | 0.08 | 0.05 | |
| Intangibles to total assets | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 170.3 | 78.67 | 150.31 | 269.65 | 61.43 | |
| ROIC | 0.01 | 0 | 0 | -0.02 | 0 | |
| Return on tangible assets | 0.01 | 0 | 0.01 | -0.02 | 0 | |
| Graham Net | 101.13 | 102.37 | 103.62 | 87.3 | 86.8 | |
| Working capital | 7.06B | 7.11B | 7.22B | 6.84B | 6.74B | |
| Tangible asset value | 11.61B | 11.7B | 11.8B | 11.8B | 11.38B | |
| Net current asset value | 5.56B | 5.55B | 5.57B | 5.07B | 5.1B | |
| Invested capital | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Average receivables | 2.69B | 3.13B | 2.98B | 2.55B | 2.55B | |
| Average payables | 862.15M | 1.01B | 922.22M | 838.81M | 924.22M | |
| Average inventory | 2.08B | 1.99B | 1.92B | 1.94B | 2.02B | |
| Days sales outstanding | 117.1 | 125.5 | 127.38 | 126.2 | 120.77 | |
| Days payables outstanding | 72.45 | 78.58 | 73.28 | 76.2 | 86.08 | |
| Days of inventory on hand | 150.97 | 147.34 | 171.84 | 173.98 | 181.21 | |
| Receivables turnover | 0.77 | 0.72 | 0.71 | 0.71 | 0.75 | |
| Payables turnover | 1.24 | 1.15 | 1.23 | 1.18 | 1.05 | |
| Inventory turnover | 0.6 | 0.61 | 0.52 | 0.52 | 0.5 | |
| ROE | 0.01 | 0 | 0.01 | -0.03 | 0 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
4512.T Frequently Asked Questions
What is Wakamoto Pharmaceutical Co.,Ltd. stock symbol ?
Wakamoto Pharmaceutical Co.,Ltd. is a JP stock and trading under the symbol 4512.T
What is Wakamoto Pharmaceutical Co.,Ltd. stock quote today ?
Wakamoto Pharmaceutical Co.,Ltd. stock price is $233 today.
Is Wakamoto Pharmaceutical Co.,Ltd. stock public?
Yes, Wakamoto Pharmaceutical Co.,Ltd. is a publicly traded company.
Company Profile
- Volume Average 156.63K
- Market Capitalization 8.05B
- Employee 403
- CEO Mr. Arata Igarashi
- Headquarters Tokyo,JP
- IPO Date 2001-01-01
-
Website
https://www.wakamoto-pharm.co.jp 
Wakamoto Pharmaceutical Co., Ltd. manufactures and sells ethical and non-prescription drugs in Japan. The company offers Strong Wakamoto, a gastrointestinal drug for digestion, intestinal regulation, and nutritional supplementation. It also provides AVANTBISE oral tablets, a supplement of bacteria to restore the balance of oral flora; and medicated toothpaste. The company was formerly known as Society for Nutrition and Raising Children Co., Ltd. and changed its name to Wakamoto Pharmaceutical Co., Ltd. in July 1943. Wakamoto Pharmaceutical Co., Ltd. was founded in 1929 and is headquartered in Tokyo, Japan.
